CME Information

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists, pharmacists, registered nurses and other allied healthcare professionals involved in the care of patients with esophageal disorders.

Learning Objectives

After completing this activity the participant should be able to:

Define the clinical presentation of complex GERD and the demographic factors driving its increasing incidence
Specify the association of inadequately controlled, symptomatic GERD with complications such as sleep disturbance, causing a deteriorating quality-of-life, and esophageal complications such as severe GERD, BE and possible EAC
Describe the management of patients with GERD co-morbidities and evaluate patients with extra-esophageal complaints who may have GERD as an underlying factor and may therefore respond to PPI therapy
Identify possible shortcomings with currently available PPIs and describe how the evolution of longer acting PPI therapy might be clinically beneficial in these patients
Describe the possible association between NERD/GERD and IBS and take a holistic approach to the management of these patients.

Certification Statement

For Physicians
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of University of California, Irvine School of Medicine and Strategic Consultants International. University of California, Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of California, Irvine School of Medicine designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For Nurses
Contact hours for registered nurses are provided by the University of California, Irvine College of Health Sciences, Program in Nursing Science as approved by the California Board of Registered Nursing, Provider Number 11349 for 1.25 contact hours.

For Pharmacists
Purdue University School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-09-149-H01-P for 1.25 contact hours (0.125 CEU).

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above.

Credit Designation Statement

Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™
Nurses - 1.25 Nursing Contact Hour(s) (0 contact hours are in the area of pharmacology)
Pharmacists - 1.25 knowledge-based ACPE (0.125 CEUs)
All other healthcare professionals completing continuing education credit for this activity will be issued a certificate of participation.

Method of participation
There are no fees for participating in and receiving credit for this activity. The participant should, in order, read the objectives and view the webcast and answer the multiple-choice post-test. Participants must obtain a score of 70% or greater to pass the post-test. In order to receive credit the participant must complete the on-line test along with the Activity Evaluation. The certificate will then be available to view and to print.

Estimated time of completion
This activity should take approximately 1.25 hours to complete. The time allocated includes the completion of reading material and completing the post-test and evaluation.

Disclosure Statements

California Assembly Bill 1195
California Assembly Bill 1195 requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. It is the intent of the bill, which went into effect on July 1, 2006, to encourage physicians and surgeons, CME providers in the state of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population through appropriate professional development. The planners, speakers and authors of this CME activity have been encouraged to address issues relevant in their topic area. Additional resources and information about AB1195 can be found on our website at http://www.cme.uci.edu.

Faculty Disclosure Statement
UCI Office of CME requires that the content of CME activities and related materials provide balance, independence, objectivity, and scientific rigor. Planning must be free of the influence or control of a commercial entity, and promote improvements or quality in healthcare. It is the policy of the UCI Office of Continuing Medical Education to insure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty participating in UCI Office of CME sponsored CME programs are expected to disclose to the activity participants any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education activity. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the course content. The intent of this policy is identifying potential conflicts of interest so participants can form their own judgments with full disclosure of the facts. It remains for the participants to determine whether the speaker’s outside interests reflect a possible bias in either the exposition or the conclusions presented.

Speaker Name	Name of Commercial Interest	Nature of Relevant Relationship	Conflict Resolution
David A. Peura, MD, MACG	Takeda Novartis Consumer Health	Consultant, Speaker Consultant	Peer review of the presentation
William D. Chey, MD, FACG	AstraZeneca, Procter & Gamble, Takeda, Xenoport Takeda	Consultant Speakers Bureau	Peer review of the presentation
Hashem B. El-Serag, MD, MPH	AstraZeneca Takeda	Consultant Independent Contractor	Peer review of the presentation
Michael F. Vaezi, MD, FACG	AstraZeneca, Takeda	Research Support	Peer review of the presentation
This educational activity may contain discussion of unlabeled and/or investigational uses of agents that are not approved by the FDA. Please consult the prescribing information for each product.
Speaker Name		Product	Product Use
Michael F. Vaezi, MD, FACG		PPIs	Extraesophageal GERD

The following planning staff have nothing to disclose:
Elena Urso, Associate Project Director, Strategic Consultants International, Hemel Hempstead, Herts, England
Alison Howe, Managing Director, Strategic Consultants International, Hemel Hempstead, Herts, England
Bonnie Carroll, Director of CME, UCI School of Medicine, Irvine, California
Robert W. Bennett, Director of CPE, Purdue University
Dawn M. Sinclair, CE Secretary, Purdue